Contents hide 1 About Revumenib 1.1 Acute Leukemia 1.1.1 Indications 1.1.2 Dosing 1.2 Dosage Modifications 1.2.1 Recommended dosage reductions 1.2.2 Differentiation syndrome 1.2.2.1 If differentiation syndrome suspected 1.2.2.2 Hold therapy 1.2.3 Noninfectious leukocytosis 1.2.4 QT prolongation 1.2.4.1 QTc interval >480-500 msec 1.2.4.2 Grade 3 QTc interval (>500 msec) 1.2.4.3 Grade 4 QTc interval (signs/symptoms of life-threatening arrhythmia) 1.2.5 Low electrolytes 1.2.5.1 Potassium 3.6-3.9 mEq/L and/or magnesium 1.7-1.9 mg/dL 1.2.5.2 Potassium ≤3.5 mEq/L and/or magnesium ≤1.6 mg/dL 1.2.6 Grade ≥3 allergic reactions 1.2.7 Grade 4 neutropenia or thrombocytopenia 1.2.8 Other Grade ≥3 nonhematologic adverse reactions 1.2.8.1 If toxicity recovers ≤7 days … Continue reading LuciRevu 160 (Revumenib)